At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.

At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.
The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…
Jessica Meek, MD, Anna Coppinger, DO, & Sejal Khan, DO |
Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…
Daniel J. Wallace, MD, & Swamy R. Venuturupalli, MD |
There was a time when medical textbooks were the ultimate resource for information in the field. The modern age of the U.S. medical textbook began in the 1920s and was fully established by the 1960s. Internal medicine saw the appearance of textbooks by Russell Cecil (1927) and Tinsley Harrison (1950), with specialty textbooks by Goodman…
Adil Vural, MD, & Kinanah Yaseen, MD |
Granulomatosis with polyangiitis (GPA) is a primary, necrotizing granulomatous vasculitis, involving small- to medium-sized arteries, that causes systemic disease. Almost any organ can be affected, but the most affected systems are the upper airways, lungs, kidneys, eyes and peripheral nerves. Migratory polyarthritis is reported in approximately 25% of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated…
Marian T. Hannan, DSc, MPH |
I vividly recollect asking my physics professor for a letter of recommendation. I sat in the front row of his lectures and visited his office hours most weeks in the semester. He turned me down because he was “too busy.” I was devastated—and panicked about asking my next choice for letter writer. On the plus…
Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.
Happy New Year, readers of The Rheumatologist! As the incoming editor, I want to welcome you back in this new year and hope that you’ll stick around, month after month, as we journey together through 2023. As the year progresses, you may notice some departures from what we have previously done, but I also wish…
The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.
PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….